LX-086

LX-086 is a novel, potent, and selective small molecule inhibitor of Unc-51 like autophagy activating kinase 1 (ULK1), currently under development by Shandong Luoxin Pharmaceutical Group. ULK1 is a serine/threonine kinase that serves as a critical initiator of the autophagy pathway, a cellular recycling process that many cancer cells exploit to survive under conditions of metabolic stress or to resist the cytotoxic effects of chemotherapy and radiotherapy. By inhibiting ULK1, LX-086 is designed to disrupt this protective survival mechanism, thereby inhibiting tumor growth and potentially sensitizing cancer cells to other therapeutic interventions. The drug is being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, focusing on safety, pharmacokinetics, and preliminary anti-tumor efficacy.